Table 2.
Antibiotic susceptibility of isolated carbapenemase-positive Gram-negative pathogens
| Pathogen | Antibiotic | n | Susceptibility n (%) | ||
|---|---|---|---|---|---|
| Sensitive | Intermediate | Resistant | |||
| Acinetobacter baumannii | Ceftazidime | 83 | 0 | 0 | 83 (100) |
| Cefepime | 83 | 0 | 3 (3.7) | 78 (96.3) | |
| Ampicillin/sulbactam | 83 | 5 (6.2) | 2 (2.5) | 78 (91.3) | |
| Levofloxacin | 83 | 1 (1.3) | 0 | 80 (98.7) | |
| Amikacin | 83 | 5 (6.2) | 1 (1.2) | 75 (92.6) | |
| Co-trimoxazole | 83 | 3 (3.7) | 0 | 78 (96.3) | |
| Colistin | 83 | 25 (30.9) | 0 | 56 (69.1) | |
| Klebsiella pneumoniae | Ceftazidime | 62 | 1 (1.6) | 1 (1.6) | 60 (96.8) |
| Cefepime | 62 | 0 | 0 | 62 (100) | |
| Piperacillin/tazobactam | 62 | 1 (1.6) | 0 | 61 (98.4) | |
| Ciprofloxacin | 62 | 2 (3.3) | 0 | 60 (96.7) | |
| Amikacin | 62 | 7 (11.3) | 1 (1.7) | 54 (87) | |
| Co-trimoxazole | 62 | 19 (30.6) | 2 (3.2) | 41 (66.1) | |
| Colistin | 62 | 19 (30.6) | 0 | 43 (69.4) | |
| Pseudomonas aeruginosa | Ceftazidime | 9 | 2 (22.2) | 0 | 7 (77.8) |
| Cefepime | 9 | 2 (22.2) | 0 | 7 (77.8) | |
| Piperacillin/tazobactam | 9 | 1 (21.2) | 0 | 8 (88.8) | |
| Ciprofloxacin | 9 | 1 (11.1) | 1 (11.1) | 7 (77.8) | |
| Amikacin | 9 | 2 (22.2) | 0 | 7 (77.8) | |
| Co-trimoxazole | 9 | 0 | 0 | 9 (100) | |
| Colistin | 9 | 5 (55.6) | 0 | 4 (44.4) | |
| Escherichia coli | Ceftazidime | 1 | 0 | 0 | 1 (100) |
| Cefepime | 1 | 0 | 0 | 1 (100) | |
| Piperacillin/tazobactam | 1 | 1 (100) | 0 | 0 | |
| Ciprofloxacin | 1 | 1 (100) | 0 | 0 | |
| Amikacin | 1 | 1 (100) | 0 | 0 | |
| Co-trimoxazole | 1 | 0 | 0 | 1 (100) | |
| Colistin | 1 | 0 | 0 | 1 (100) | |